INmune Bio
Stock Forecast, Prediction & Price Target
INmune Bio Financial Estimates
INmune Bio Revenue Estimates
INmune Bio EBITDA Estimates
INmune Bio Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $181K N/A | $374K 106.62% | $155K -58.55% | Avg: $29K Low: $9.66K High: $58K avg. -81.29% | Avg: $29.5K Low: $9.83K High: $59K avg. 1.72% | Avg: $82.70M Low: $27.56M High: $165.41M avg. 280259.32% | Avg: $146.16M Low: $48.72M High: $292.33M avg. 76.72% |
Net Income
% change YoY
| $-30.34M N/A | $-28.64M 5.58% | $-30.00M -4.75% | Avg: $-48.46M Low: $-48.00M High: $-43.87M avg. -61.51% | Avg: $-49.05M Low: $-48.54M High: $-39.73M avg. -1.20% | Avg: $24.45M Low: $3.26M High: $56.24M avg. 149.85% | Avg: $73.09M Low: $9.74M High: $168.11M avg. 198.89% |
EBITDA
% change YoY
| $-29.15M N/A | $-25.95M 10.98% | $0 100% | Avg: $-24.00K Low: $-48.01K High: $-8.00K avg. 0% | Avg: $-24.42K Low: $-48.84K High: $-8.14K avg. -1.72% | Avg: $-68.47M Low: $-136.94M High: $-22.82M avg. -280262.09% | Avg: $-121.01M Low: $-242.02M High: $-40.33M avg. -76.72% |
EPS
% change YoY
| -$1.88 N/A | -$1.6 14.89% | -$1.67 -4.37% | Avg: -$2.56 Low: -$2.67 High: -$2.44 avg. -52.99% | Avg: -$2.46 Low: -$2.7 High: -$2.21 avg. 3.91% | Avg: $1.36 Low: $0.18 High: $3.13 avg. 155.39% | Avg: $4.07 Low: $0.54 High: $9.35 avg. 198.89% |
Operating Expenses
% change YoY
| $29.33M N/A | $26.32M -10.25% | $29.89M 13.56% | Avg: $4.14M Low: $1.38M High: $8.28M avg. -86.13% | Avg: $4.21M Low: $1.40M High: $8.43M avg. 1.72% | Avg: $11.81B Low: $3.93B High: $23.63B avg. 280259.32% | Avg: $20.88B Low: $6.96B High: $41.77B avg. 76.72% |
FAQ
What is INmune Bio stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 71.50% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -48.00M, average is -48.46M and high is -43.87M.
What is INmune Bio stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 70064.12% in 2025-2028.
We have gathered data from 2 analysts. Their low revenue estimate is $9.66K, average is $29K and high is $58K.
What is INmune Bio stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 76.30% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$2.67, average is -$2.56 and high is $-2.44.